Literature DB >> 12654770

In vitro susceptibility to a new antimalarial organometallic analogue, ferroquine, of Plasmodium falciparum isolates from the Haut-Ogooué region of Gabon.

Christiane Atteke1, Jérôme Mezui Me Ndong, Agnès Aubouy, Lucien Maciejewski, Jacques Brocard, Jacques Lébibi, Philippe Deloron.   

Abstract

OBJECTIVES: To assess the activity of a new organometallic chloroquine analogue, ferroquine, against numerous Plasmodium falciparum isolates from Gabon.
METHODS: The in vitro susceptibility of 116 P. falciparum isolates to chloroquine and ferroquine was assessed using the isotopic microtest. All isolates were from outpatients in the Franceville and Bakoumba medical centres in the province of Haut-Ogooué, south-east Gabon.
RESULTS: The in vitro resistance to chloroquine was 51.8% in Franceville and 96.7% in Bakoumba. The IC50 geometric mean (95% CI) of ferroquine against isolates in Franceville was 16.0 (14.4-17.8) nM, with individual values ranging from 1.0 to 47.0 nM; in Bakoumba it was 27.9 (23.4-33.2) nM, with individual values ranging from 1.0 to 62.0 nM. Compared with chloroquine, ferroquine was 5.3 times more active on isolates susceptible to chloroquine, and 13.3 times more active on isolates resistant to chloroquine. A weak positive correlation was observed between responses of these two drugs, but too low to demonstrate cross-resistance.
CONCLUSIONS: Ferroquine may be useful as an alternative drug for treating chloroquine-resistant malaria.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12654770     DOI: 10.1093/jac/dkg161

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

1.  Inhibitory activity of ferroquine, versus chloroquine, against western Kenya Plasmodium falciparum field isolates determined by a SYBR Green I in vitro assay.

Authors:  Fredrick L Eyase; Hoseah M Akala; Jacob D Johnson; Douglas S Walsh
Journal:  Am J Trop Med Hyg       Date:  2011-12       Impact factor: 2.345

2.  Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P. vivax.

Authors:  Jutta Marfurt; Ferryanto Chalfein; Pak Prayoga; Frans Wabiser; Enny Kenangalem; Kim A Piera; Barbara Machunter; Emiliana Tjitra; Nicholas M Anstey; Ric N Price
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

3.  Pharmacokinetics of ferroquine, a novel 4-aminoquinoline, in asymptomatic carriers of Plasmodium falciparum infections.

Authors:  Christian Supan; Ghyslain Mombo-Ngoma; Matthias P Dal-Bianco; Carmen L Ospina Salazar; Saadou Issifou; Florent Mazuir; Aziz Filali-Ansary; Christophe Biot; Daniel Ter-Minassian; Michael Ramharter; Peter G Kremsner; Bertrand Lell
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

4.  Plasmodium vivax susceptibility to ferroquine.

Authors:  M L Leimanis; A Jaidee; K Sriprawat; S Kaewpongsri; R Suwanarusk; M Barends; A P Phyo; B Russell; L Renia; F Nosten
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

5.  Phase 2a, Open-Label, 4-Escalating-Dose, Randomized Multicenter Study Evaluating the Safety and Activity of Ferroquine (SSR97193) Plus Artesunate, versus Amodiaquine Plus Artesunate, in African Adult Men with Uncomplicated Plasmodium falciparum Malaria.

Authors:  Christian Supan; Ghyslain Mombo-Ngoma; Maryvonne Kombila; Carmen L Ospina Salazar; Jana Held; Bertrand Lell; Cathy Cantalloube; Elhadj Djeriou; Bernhards Ogutu; John Waitumbi; Nekoye Otsula; Duncan Apollo; Mark E Polhemus; Peter G Kremsner; Douglas S Walsh
Journal:  Am J Trop Med Hyg       Date:  2017-07-19       Impact factor: 2.345

6.  In vitro activity of ferroquine is independent of polymorphisms in transport protein genes implicated in quinoline resistance in Plasmodium falciparum.

Authors:  Maud Henry; Sébastien Briolant; Albin Fontaine; Joel Mosnier; Eric Baret; Rémy Amalvict; Thierry Fusaï; Laurent Fraisse; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2008-05-27       Impact factor: 5.191

Review 7.  The antimalarial ferroquine: from bench to clinic.

Authors:  C Biot; F Nosten; L Fraisse; D Ter-Minassian; J Khalife; D Dive
Journal:  Parasite       Date:  2011-08       Impact factor: 3.000

8.  N-(Ferrocenylmethyl)-dodecan-1-amine.

Authors:  Li-Zhen Sun; Wei An; Hua-Cheng Zhang; Fei-Fei Xin; Ai-You Hao
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-02-13

9.  Phase I randomized dose-ascending placebo-controlled trials of ferroquine--a candidate anti-malarial drug--in adults with asymptomatic Plasmodium falciparum infection.

Authors:  Ghyslain Mombo-Ngoma; Christian Supan; Matthias P Dal-Bianco; Michel A Missinou; Pierre-Blaise Matsiegui; Carmen L Ospina Salazar; Saadou Issifou; Daniel Ter-Minassian; Michael Ramharter; Maryvonne Kombila; Peter G Kremsner; Bertrand Lell
Journal:  Malar J       Date:  2011-03-01       Impact factor: 2.979

10.  Assessment of Plasmodium falciparum resistance to ferroquine (SSR97193) in field isolates and in W2 strain under pressure.

Authors:  Wassim Daher; Christophe Biot; Thierry Fandeur; Helene Jouin; Lydie Pelinski; Eric Viscogliosi; Laurent Fraisse; Bruno Pradines; Jacques Brocard; Jamal Khalife; Daniel Dive
Journal:  Malar J       Date:  2006-02-07       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.